May 19, 2020

Assange Turns to PM Gillard for Protection

Business
Australia
WikiLeaks
United States
Bizclik Editor
2 min
Assange Turns to PM Gillard for Protection

Last week, WikiLeaks’ founder Julian Assange made headlines when he turned to Ecuador’s London embassy for asylum in an effort to avoid extradition to Sweden, where he is wanted for questioning about two sexual assault allegations dating back to August 2010.

This week, the Aussie is seeking protection from his native country, calling on Prime Minister Julia Gillard to exercise her federal power to protect him from the Swedish courtroom.

From Sweden, he fears that he’ll be handed to the United States’ authorities to stand trial as a result of WikiLeaks’ publishing of more than 25,000 confidential diplomatic documents in 2010, but Australian Foreign Minister Bob Carr assures that he has received “no hint” of this actually happening.

SEE RELATED STORIES FROM THE WDM CONTENT NETWORK:

Click here to read the latest issue of  Business Review Australia

Still, Mr Assange isn’t taking any chances.

''I have been attacked by the US, from the Vice-President down, as a high-tech terrorist, and by the Swedish Prime Minister and Foreign Minister - surely that requires some direct response from the Gillard government,” he told Fairfax Media.

According to the Herald Sun, Labor diplomats has been in “constant contact” with Mr Assange’s legal team and have offered face-to-face meetings with him, but Ms Gillard said he has never requested one.

"In the course of these legal proceedings, my advice is consular officials have been in contact with his legal team and Mr Assange has not requested or sought for those dealings to be directly with him,” Ms Gillard told the newspaper.

"Mr Assange has received continuing consular assistance in exactly the same way any Australian citizen facing legal issues would.”

The former computer hacker is currently waiting for his asylum application to be processed by the Ecuadorean government in hopes that the President, Rafael Correa, will provide him with adequate protection should the Australian Government fail to do so.

Share article

Jun 13, 2021

Seo JungJin: Who is EY’s World Entrepreneur of 2021?

EY
entrepreneurs
Leadership
celltrion
Kate Birch
3 min
From just US$45,000 capital in 2003 to a world-leading biopharma giant with revenues of US$1.69bn today, Seo JungJin is crowned EY World Entrepreneur 2021

Seo JungJin, founder of biopharma firm Celltrion, which most recently developed an antibody treatment for COVID-19, has been named the EY World Entrepreneur of the Year 2021, becoming the first South Korean in the award’s 21-year history.

Regarded as one of the world’s most prestigious business awards program for entrepreneurs, the EY Entrepreneur of the Year celebrates visionary and innovative leaders from across 60 countries who are transforming the world and fostering growth.

JungJin, who is now honoroary chairman of Celltrion Group, was up against a worthy cast of entrepreneurial competitors, taking the crown from among 45 award winners across 38 countries and territories.

Speaking during the virtual event, JungJin described his own interpretation of entrepreneurship as something that brings together “a group of people toward a common vision, embracing challenges as opportunities and committing oneself to contribute to the greater good”.

Why was JungJin crowned King Entrepreneur?

A South Korean native and now 63 years of age, JungJin founded biopharmaceutical firm Celltrion in 2003. In the nearly two decades since its founding, Celltrion has lived up to its goal of advancing health and welfare for all by developing ground-breaking drugs to treat autoimmune disease, various forms of cancer and, most recently, COVID-19.

The company, which JungJin started with just US$45,000 and five of his colleagues, has since growth to more than 2,1000 employees with sales permits in more than 90 countries and revenues exceeding US$1.69bn.

According to the panel, JungJin’s story is a shining example of the power of an unstoppable entrepreneur to change the world with the pandel moved by both his incredible story and his purpose-driven leadership, innovative mindset and entrepreneurial spirit.

Described by the chair of the EY judging panel Rosaleen Blair as “representing everything an unstoppable should be” from taking on the world’s biggest health care challenges to consistently creating long-term value for his company, JungJin’s story is one of incredible tenacity and perseverance that the judging panel felt most represented the entrepreneurial spirit.

“He’s taken breathtaking risks, both personal and professional, to found Celltrion and grow it into one of the world’s leading biopharmaceutical companies,” says Stasia Mitchell, EY Global Entrepreneurship Leader. “His passion for creating affordable, life-saving health care and flair for tackling global problems has led to many treatments that have helped millions of people worldwide and was especially evident this past year through the creation of a COVID-19 antibody treatment.”

How did JungJin get there?

JungJin's entrepreneurial journey started at an early age when he worked as a taxi driver to get himself through Konkuk University in Seoul, South Korea. After studying industrial engineering, he rose through the ranks of Daewoo Motor Co. before losing his job amid the carmaker’s financial troubles following the 1997 Asian economic crisis.

Following this, JungJin started collaborating with colleagues to explore business opportunities in different industries, though none delivered lasting success. The turning point came after he attended a talk hosted by renowned scholars, which inspired him to focus on the biopharmaceutical sector.

And so he founded Celltrion with just US$45,000 of his savings. The launch of Remsima, credited with being the world's first antibody biosimilar, quickly moved Celltrion up the ranks of the country's fairly underdeveloped pharmaceutical sector. Celltrion followed this success with the launch of drugs for breast cancer and lymphoma that today are being used worldwide.

With ambitions to be the world’s first in different areas, Celltrion has pioneered numerous uncharted areas to great success over the past two decades, most recently responding to the global pandemic by successfully developing an antibody treatment for COVID-19 and working to ensure a timely supply of the safe and effective treatment.

“When I first started, my vision was to help patients gain access to safe, effective and affordable medicines and thereby enhance the quality of people’s lives,” explains JungJin. “The success of Celltrion has enabled me to expand on this while finding new ways to fuel my entrepreneurial drive.”

 

Share article